Sandra Meyer

The German network of excellence for viral hepatitis (Hep-Net).

Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans.

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN.

Discovery of complex mixtures of novel long-chain quorum sensing signals in free-living and host-associated marine alphaproteobacteria.

One-step biotinylation procedure for carbohydrates to study carbohydrate-protein interactions.

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

The C-type lectin L-SIGN differentially recognizes glycan antigens on egg glycosphingolipids and soluble egg glycoproteins from Schistosoma mansoni.

Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".

Resistance profile of darunavir: combined 24-week results from the POWER trials.

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

Transglycosylation-based fluorescent labeling of 6-gala series glycolipids by endogalactosylceramidase.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

Multipotent adult germline stem cells and embryonic stem cells: comparative proteomic approach.

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240.

Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts.

Glycolytic metabolism and tumour response to fractionated irradiation.

[Diagnosis of delirium].

[Drug-induced delirium].

Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.

Schistosoma mansoni worm glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN.

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.

Digital gene expression signatures for maize development.

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Multipotent adult germline stem cells and embryonic stem cells functional proteomics revealed an important role of eukaryotic initiation factor 5A (Eif5a) in stem cell differentiation.

Telaprevir for retreatment of HCV infection.

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Duplicated STM-like KNOX I genes act in floral meristem activity in Eschscholzia californica (Papaveraceae).

Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Synthesis and pharmacological evaluation of a new series of radiolabeled ligands for 5-HT7 receptor PET neuroimaging.

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.

Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.

Modeling viral evolutionary dynamics after telaprevir-based treatment.

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

Effect of Agrobacterium strain and plasmid copy number on transformation frequency, event quality and usable event quality in an elite maize cultivar.

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY.

An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.